Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line

References

• Janku F, Stewart D, Kurzrock R. Targeted therapy in non-small-cell lung cancer – is it becoming a reality? Nat Rev Clin Oncol. 2011;8:384.
   Web of Science ®Google Scholar
• Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128.
   PubMed Web of Science ®Google Scholar
• Lam WK, Watkins DN. Lung cancer: future directions. Respirology. 2007;12:471–477.
   PubMed Web of Science ®Google Scholar
• Rami-Porta R, Crowley JJ, Goldstraw P. Review the revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15:5.
   Web of Science ®Google Scholar
• Fathi Karkan S, Mohammadhosseini M, Panahi Y, et al. Magnetic nanoparticles in cancer diagnosis and treatment: a review. Artif Cells, Nanomed Biotechnol. 2016.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
   PubMed Web of Science ®Google Scholar
• Lu R-M, Chang Y-L, Chen M-S, et al. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 2011;32:3265–3274.
   PubMed Web of Science ®Google Scholar
• Gualberto A, Karp DD. Development of the monoclonal antibody Figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non–small-cell lung cancer. Clin Lung Cancer. 2009;10:273–280.
   PubMed Web of Science ®Google Scholar
• Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids. 2012 [Epub ahead of print]. DOI: 10.1155/2012/967347.
   PubMedGoogle Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2:750–763.
   PubMed Web of Science ®Google Scholar
• Badrzadeh F, Rahmati-Yamchi M, Badrzadeh K, et al. Drug delivery and nanodetection in lung cancer. Artif Cells Nanomed Biotechnol. 2016;44:618–634.
   PubMed Web of Science ®Google Scholar
• Babu A, Templeton AK, Munshi A, et al. Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. J Nanomater. 2013. Article ID 863951.
   Web of Science ®Google Scholar
• des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116:1–27.
   PubMed Web of Science ®Google Scholar
• Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, et al. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomed Biotechnol. 2016;44:1051–1061.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. ColloidSurf B Biointer 2010;75:1–18
   PubMed Web of Science ®Google Scholar
• Siahmansouri H, Somi MH, Babaloo Z, et al. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT‐29 colorectal cancer cell line. J Pharm Pharmacol 2016;68:1119–1130.
   PubMed Web of Science ®Google Scholar
• Dass CR, Choong PF. The use of chitosan formulations in cancer therapy. J Microencapsul. 2008;25:275–279.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang Y, Ma Q, et al. Development and characterization of folic acid-conjugated chitosan nanoparticles for targeted and controlled delivery of gemcitabinein lung cancer therapeutics. Artif Cells Nanomed Biotechnol 2016 [Epub ahead of print]. DOI: 10.1080/21691401.2016.1260578
   Web of Science ®Google Scholar
• Mehrotra A, Nagarwal RC, Pandit JK. Lomustine loaded chitosan nanoparticles: characterization and in-vitro cytotoxicity on human lung cancer cell line L132. Chem Pharm Bull. 2011;59:315–320.
   PubMed Web of Science ®Google Scholar
• Denduluri SK, Idowu O, Wang Z, et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2015;2:13–25.
   PubMed Web of Science ®Google Scholar
• Shali H, Ahmadi M, Kafil HS, et al. IGF1R and c-met as therapeutic targets for colorectal cancer. Biomed Pharmacother. 2016;82:528–536.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev. 2012;38:292–302.
   PubMed Web of Science ®Google Scholar
• Fidler MJ, Shersher DD, Borgia JA, et al. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol. 2012;4:51–60.
   PubMed Web of Science ®Google Scholar
• Lee Y, Wang Y, James M, et al. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells. Molec Carcinogenesis. 2016;55:991–1001.
   PubMed Web of Science ®Google Scholar
• Qian J, Dong A, Kong M, et al. Suppression of type 1 Insulin-like growth factor receptor expression by small interfering RNA inhibits A549 human lung cancer cell invasion in vitro and metastasis in xenograft nude mice. Acta Biochim Biophys Sinica. 2007;39:137–147.
   PubMed Web of Science ®Google Scholar
• Jadidi-Niaragh F, Atyabi F, Rastegari A, et al. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. Tumor Biol. 2016;37:8403–8412.
   PubMed Web of Science ®Google Scholar
• Zhang D, Samani A, Brodt P. The role of the IGF-I receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis. Hormone Metab Res. 2003;35:802–808.
   PubMed Web of Science ®Google Scholar
• King ER, Wong K-K. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov. 2012;7:14–30.
   PubMed Web of Science ®Google Scholar
• Riedemann J, Macaulay V. IGF1R signalling and its inhibition. Endocrine-Related Cancer. 2006;13(Supplement 1):S33–S43.
   PubMedGoogle Scholar
• Morgillo F, Della Corte CM, Fasano M, et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1:e000060.
   PubMed Web of Science ®Google Scholar
• Linnerth NM, Siwicky MD, Campbell CI, et al. Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia. 2009;11:672–682.
   PubMed Web of Science ®Google Scholar
• Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 2005;113:316–328.
   PubMed Web of Science ®Google Scholar
• Cosaceanu D, Carapancea M, Castro J, et al. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett. 2005;222:173–181.
   PubMed Web of Science ®Google Scholar
• Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett. 2005;579:5996–6007.
   PubMed Web of Science ®Google Scholar
• Miyagishi M, Taira K. U6 promoter–driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol. 2002;20:497–500.
   PubMed Web of Science ®Google Scholar
• Wang C, Ding C, Kong M, et al. Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem Biophys Res Commun. 2011;410:537–542.
   PubMed Web of Science ®Google Scholar
• Yin M, Guan X, Liao Z, et al. Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res. 2009;1:101–114.
   PubMed Web of Science ®Google Scholar
• Nian W, Ao X, Wu Y, et al. miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncol Lett. 2013;6:359–366.
   PubMed Web of Science ®Google Scholar
• Gariboldi MB, Ravizza R, Monti E. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol. 2010;80:455–462.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zong CS, Hermanto U, et al. RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth. Molec Cell Biol. 2006;26:413–424.
   PubMed Web of Science ®Google Scholar